An exemplary embodiment of the present specification provides an organic electroluminescence device including: an anode; a cathode; a light emitting layer provided between the anode and the cathode; and an electron transporting layer provided between the cathode and the light emitting layer, in which the electron transporting layer includes a first electron transporting material and a second electron transporting material, the first electron transporting material is an organic material including a monocyclic or polycyclic ring which includes an N-containing six-membered ring, the second electron transporting material is an organic material including a five-membered hetero ring which includes at least one heteroatom of N, O, and S, or a cyano group, and a dipole moment of the second electron transporting material is larger than a dipole moment of the first electron transporting material.

An exemplary embodiment of the present specification provides an organic electroluminescence device including: an anode; a cathode; a light emitting layer provided between the anode and the cathode; and an electron transporting layer provided between the cathode and the light emitting layer, in which the electron transporting layer includes a first electron transporting material and a second electron transporting material, the first electron transporting material is an organic material including a monocyclic or polycyclic ring which includes an N-containing six-membered ring, the second electron transporting material is an organic material including a five-membered hetero ring which includes at least one heteroatom of N, O, and S, or a cyano group, and a dipole moment of the second electron transporting material is larger than a dipole moment of the first electron transporting material.

Compounds of the formula I ##STR00001## in which R.sup.1, R.sup.4, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Compounds of the formula I ##STR00001## in which R.sup.1, R.sup.4, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

This disclosure relates to luciferin amides of formula (I) shown below: ##STR00001##
Each variable in formula (I) is defined in the specification. These compounds can be used to detect fatty acid amide hydrolase activities in vitro, in live cells, or in vivo.

This disclosure relates to luciferin amides of formula (I) shown below: ##STR00001##
Each variable in formula (I) is defined in the specification. These compounds can be used to detect fatty acid amide hydrolase activities in vitro, in live cells, or in vivo.

This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

A fluorinated 2-arylbenzo heterocyclic compound with high affinity to Aβ plaques and containing a chiral side chain substituent, has a general formula (I) as follows: ##STR00001## wherein X is N; Y is S or O; Z is N or CH; R.sub.1 is a 5 or 6-substituent and is ##STR00002##
F is .sup.19F or .sup.18F; R.sub.2 is NHCH.sub.3 or N(CH.sub.3).sub.2. The compound of the present invention has high affinity to Aβ plaques and can be used to make appropriate radioactive nuclide labeling probes for early diagnosis of AD.

A fluorinated 2-arylbenzo heterocyclic compound with high affinity to Aβ plaques and containing a chiral side chain substituent, has a general formula (I) as follows: ##STR00001## wherein X is N; Y is S or O; Z is N or CH; R.sub.1 is a 5 or 6-substituent and is ##STR00002##
F is .sup.19F or .sup.18F; R.sub.2 is NHCH.sub.3 or N(CH.sub.3).sub.2. The compound of the present invention has high affinity to Aβ plaques and can be used to make appropriate radioactive nuclide labeling probes for early diagnosis of AD.